Objective: Overactive bladder is a common disease for which current pharmaceutical therapy is often unsatisfactory. Newer modalities, including Botox and InterStim, can be used when antimuscarinics fail. We compare InterStim and Botox using decision analysis.
O veractive bladder is a very common disease, and one for which we frequently cannot find a suitable management. Antimuscarinic medications have been the mainstay of treatment, but discontinuation rates are often more than 75% at 1 year because of adverse effects such as dry mouth and constipation. Newer modalities have been developed, including Botox (Allergan, Irvine, Calif) and InterStim (Medtronic, Minneapolis, Minn).
Botox (botulinum-A toxin) injected into the detrusor muscle causes paralysis of the muscle. It is effective in approximately 75% of people, 1 but results tend to fade over time with reappearance of symptoms in less than 1 year. 2, 3 Adverse effects include transient retention requiring self-catheterization. This does not seem to alter quality of life compared with the improvement from controlling the urinary urgency. 4, 5 Urinary tract infections also develop with greater frequency compared with placebo. Repeat injections have been performed with similar efficacy. 6 InterStim is a device similar to a pacemaker that generates a pulse that stimulates the S3 sacral nerve. Its mechanism of action is incompletely understood. In a 2-stage procedure, a needle electrode is inserted, and the patient is tested to see if he/she responds via a percutaneous stimulator. If this is successful, the permanent pulse generator is implanted. Success rates of 55% to 65% are seen from 6 months to 5 years of follow-up. 7, 8 The device will have to be revised in approximately 25% and explanted in 10%. 9, 10 Reasons for revision or explantation include infection (4%), pain (11%), unwanted sensation of electrical shock (5%), and lead migration (5%).
Although the success rates of these procedures seem low, they are being used in patients who have failed standard therapy. We must also consider similar success rates between procedures weighed against reinjection rates with Botox and the explantation/revision rates with InterStim. However, no headto-head trials have been performed. In an effort to overcome this shortcoming, we performed a decision analysis, which is a systematic, evidenced-based method to compare 2 strategies, each with supporting literature but with no comparative literature to date.
MATERIALS AND METHODS
We consulted with our institutional review board, who stated that their review was not needed because decision analysis is not considered a human subject research. We have no disclosures or conflicts of interest. We used decision analysis software (TreeAge Pro; TreeAge Software, Inc, Williamstown, Mass). A decision tree was constructed to compare Botox and InterStim for overactive bladder refractory to antimuscarinics. Markov state transition modeling was used to simulate all possible states with combinations of outcomes relevant to each therapy. For example, a patient could move from being cured from InterStim and then develop pain or have lead migration, which would lead to InterStim failure necessitating device revision. An alternative example would be the patient who undergoes successful Botox but then develops retention requiring self-catheterization, which leads to a urinary tract infection (UTI). Our model was based on 54 months of follow-up with transition between states occurring every month.
A literature search was performed using PubMed to find probabilities for each of the relevant outcomes. We searched using MeSH terms ''urge incontinence'' or ''overactive bladder'' combined with Boolean operator ''and'' with the MeSH term ''Botox'' or ''botulinum toxin.'' There was no MeSH term for either ''sacral neuromodulation'' or ''InterStim.'' We also searched key words including ''urge incontinence'' or ''overactive bladder'' combined using Boolean operator ''and'' with ''InterStim,'' ''sacral neuromodulation,'' ''botulinum toxin,'' or ''Botox.'' Abstracts were reviewed to eliminate unsuitable articles, and full-text articles were used to confirm potentially suitable articles. The references of included articles were reviewed to identify other articles.
The base case values used for the model were a composite of all available articles. The articles used are listed in Appendix 1. Of note, for articles whose subjects had both neurogenic and nonneurogenic urge incontinence, only the data from nonneurogenic patients were used. These 2 populations are likely very different, and this study aimed to compare 2 strategies for patients with nonneurogenic urge incontinence. For the purposes of the model, TreeAge Pro was used to convert the probabilities reported in the literature into a monthly probability used in our Markov state transition modeling. Corrections were also made in the model to account for the probability of having 2 independent events occur simultaneously. Table 1 contains the base case efficacy and complication values.
Corrections were also made in the model to account for the fact that certain transitions between states were not practical. For example, the base case probability for needing to self-catheterize with Botox was 37.7%. However, if Botox is successful for 6 months, the likelihood of having to self-catheterize in the following month is much lower than this base case probability.
Next, values were assigned to each of the utilities, which range from 0 to 1 (0 = dead, 1 = perfect health). Because utility values for urge incontinence were not available in the literature, these were assigned by an expert panel of 6 urogynecologists. The technique used has been described previously. 11 Each expert panelist was given 2 articles listing utility values for common conditions, and each was instructed to find a similar condition to each of the utility conditions used in the model. 12,13 These published utility values were then used as a surrogate utility for the condition in the model. We decided to use these surrogate values to help reduce the arbitrary nature of physician-assigned utility values. We report the median values of the panel. However, summary statistics showed that the mean values were never more than 5% different from the median. Table 2 contains a list of conditions with utility values.
Utility values are based on a 1-year time frame. This allows conversion of a utility of 1 to an equivalent quality-adjusted life-year (QALY). However, our Markov model used state transitions on a 1-month period. Conversions were made so that the utility was changed into a monthly disutility value. For example, a yearly utility of 0.88 would equate to a yearly disutility of 0.12 for a monthly disutility of 0.01. In this way, the disutility of multiple complications can also be combined in the model. For example, if condition A has utility 0.8 and condition B has utility 0.8, the Markov state, which combined these 2 conditions, would have a yearly utility of 0.8 Â 0.8 = 0.64 for a yearly disutility of 0.36 and a monthly disutility of 0.03. Yearly utility, which equates to QALYs, is 1 minus the sum of the 12 monthly disutilities.
Several assumptions were used when constructing the Markov state transition model. For the InterStim branch, if infection developed the device was always removed. If pain developed, the device was either revised or removed. If the device failed, it was sometimes revised/removed but sometimes left in situ. For the Botox branch, we assumed that Botox therapy lasted for 9 months and that self-catheterization had 4 months in duration. Both durations were chosen based on the articles in Appendix 1. If a UTI developed, it resolved by the next 1-month cycle. Botox injections were repeated for failed treatments only if there was no UTI, the patient was not currently self-catheterizing, and the time since the last Botox injection was at least 6 months. Once a patient failed twice, the injections were not repeated.
Because the percentage of patients who were dry after Botox therapy (65.4%) was similar to the percentage whose symptoms were improved or absent (63.5%); there were few patients whose symptoms were improved but who were not dry. This is different from observations with InterStim and shows that Botox is more dichotomous in its success with less of a continuum as seen with InterStim. Therefore, Botox was considered as either successful or failure, and no intermediate Markov states were used.
Differences between the cumulative and average 1-year utility were then compared with the minimally important difference (MID) for utility values. The MID for overall utility is 0.058 and 0.048 for 2 separate health utility measures on a scale of 0 to 1.
14 Differences less than this minimum value are thought to be clinically insignificant, and their importance was discounted.
The robustness of the model was tested using multiple 1-way sensitivity analyses, calculating the threshold value of each variable where model results went from favoring one strategy to favoring the other. As Botox was favored for every period, this involved determining how much lower the success rates or higher the complication rates for Botox or how much higher the success rates or lower the complication rates for InterStim would have to be in order for InterStim to become the favored strategy. Thresholds were determined for all utility values and all probabilities. Of note, the probabilities were different for each outcome based on the state they were currently in. From the example in the methods section, the probability of needing to self-catheterize with Botox was much higher if one just underwent injection than if one has been successfully treated for 6 months. Therefore, thresholds were calculated for all probabilities at all possible Markov states.
RESULTS
Our model terminated after a period of 54 months, corresponding to the average InterStim battery life, at which point an additional operation would be necessary to replace the battery. Figure 1 shows the cumulative utility for each of the 54 months. Notably, Botox has a higher utility than InterStim at all time points, but the difference between strategies is always less than the MID.
We further evaluated our model with multiple 1-way sensitivity analyses to detect thresholds (ie, the point at which the model would switch to favor InterStim instead of Botox). This included the 22 different utility values as well as all transition probabilities from each of 23 different states. In most cases, no threshold was identified. The thresholds identified are listed in Table 3 .
DISCUSSION
In our decision analysis, we used Markov transition states to compare InterStim and Botox for refractory urge incontinence and determined that Botox has a higher overall utility at all time points during the 54-month period. However, the difference between the 2 strategies was always less than the MID. This means that the 2 strategies are highly comparable. When differences in a decision analysis are less than the MID, this can be likened to a clinical trial with a statistically insignificant difference between therapies.
It is important to realize that decision analyses are hypothetical constructs that cannot be used as definitive answers to clinical questions. However, they can be used to help direct clinical decision-making. In a situation such as this one, they are especially helpful to compare 2 strategies where there is a lack of data from head-to-head clinical trials. Data from trials that demonstrate efficacy and complications from each of the strategies individually can be combined into a model that will effectively evaluate both strategies simultaneously.
Markov state transition modeling is particularly appropriate in this scenario. With Botox, the effectiveness of the therapy is only temporary, lasting on average 9 months. Complications such as urinary retention are also transient. With InterStim, the device has to be removed or revised not infrequently. Markov state transition modeling allows transitions between these different situations with returns to previous states, as often seen in this clinical scenario. It also allows definition of time duration in each state and the number of transitions that are executed in the model. We chose 54 months as the period for this model because this was the average battery life for InterStim. After the battery is depleted, another operation is required to replace the pulse generator. We could alternatively have required all model participants to undergo a revision after 54 months but felt that this was a suitable end point for the analysis. After this point, no additional utility could be gained without the disutility of surgical intervention. Likewise, ending the study before this period would rob InterStim of cumulative utility. If no new complications develop, the InterStim group would continue to benefit from the disutility of the initial surgery until the battery is depleted.
Recently, a cost-effectiveness analysis compared these 2 strategies. 15 Our model differs from this study on several fronts. First, ours is solely utility-based, which does not account for costs. However, our model transitions between states more rapidly (monthly as opposed to every 3 months), which would better account for transient complications with these operations. Our model accounts for more health states with separate states for every complication or combination of complications with associated utility values. Whereas the cost-effectiveness model has 4 health states for each strategy, our model incorporates 13 states for InterStim and 9 for Botox. With more complexity, we were more closely able to model reality and accounted for complication combinations as opposed to addressing all complications under one umbrella.
Another important difference is the use of physicianassigned utility values in our model, although our method has been described previously. 11 There is conflicting literature about physician-derived utility values. In some studies, the physicians rated utility lower than patients did. 16 In other studies, they consistently rated utilities higher than the parents of pediatric patients did. 17 In both of these scenarios, the rank order of utility values was consistent between both groups. This means that if the patient rated condition A with higher utility than condition B but lower utility than condition C, the physician would do likewise. Because we were unable to find published data on utility for urogynecologic complaints, we feel this was an adequate surrogate for this model. A difference in utility value would affect the overall cumulative utility, but the inflation or reduction should be consistent between the 2 strategies, and the overall difference in cumulative utility should not have been affected.
The expert panel seemed to give Botox slightly higher utility values than InterStim. This is possibly due to bias if Botox was their preferred strategy. This is doubtful because none of them were performing Botox at the time of this analysis, but InterStim was routinely performed by 4 of the 6. It is also possible that Botox was rated higher because it was thought to be less invasive. Another observation is that the panel rated all states relatively highly, with the lowest utility of 0.68 for ''Botox fails for incontinence, self-catheterization required, UTI develops.'' This, however, was borne out in the literature for known published utilities. For example, the condition of being impotent and incontinent after transurethral resection of the prostate for benign prostatic hypertrophy has a utility of 0.6. 12 Even if utility values were overestimated, previous research has shown that the rank order should be the same, 16, 17 and the sensitivity analysis performed should detect any fluctuations that would change model outcomes.
The threshold values identified show several key findings. It is fairly intuitive that reducing the utility for the favored strategy of Botox changes model results. However, increasing the utility for InterStim-related events did not produce a threshold. This is because baseline utility for both strategies is relatively high, and it was impossible to increase the utility beyond 1.00 (perfect health) in our sensitivity analysis. It is also intuitive that increasing the complications of Botox, reducing the efficacy of Botox, and increasing the efficacy of InterStim should shift the model to favor InterStim and produce a threshold value. However, most of these thresholds occur at clinically unreasonable values. For example, if Botox failed 50% of the time (threshold value) instead of the base case 17.1%, we would likely not use this therapy.
Another observation from the threshold values is seen when transitioning from InterStim failure to failure with pain. On the basis of the base case of 0.004 and threshold of 0.414, InterStim would have a higher cumulative utility if there was a higher chance of pain developing, seemingly counterintuitive. However, in our model, patients were more likely to undergo a revision if they had pain than if they just had InterStim failure. These people were likely to get better results after a revision, Ultimately, there were very few threshold values given the vast number of 1-way sensitivity analyses performed. Many of the thresholds were either not clinically meaningful or fell outside the range for that variable seen in the literature search, which makes them less valid. This would suggest that our model was very robust and not very sensitive to changes in the assumptions on which it was built, yielding strength to the conclusions drawn.
Another item that may influence physician decisions other than utility is generalized acceptance of the therapy. InterStim has approval from the Food and Drug Administration for the treatment of refractory overactive bladder. Botox does not yet have this approval, although its off-label use has proven effective. In a model where there was no clinically important difference between the 2 therapies, this may be a deciding factor for some physicians. Physicians may also be influenced by their comfort level with fluoroscopic and cystoscopic techniques or their comfort in treating the different adverse effects from the 2 procedures.
CONCLUSIONS
All in all, we were not able to demonstrate any real overall utility difference between the 2 strategies. They have very different adverse effects but similar efficacy, with improvement rates of 63.5% for Botox and 58.5% for InterStim. They both have high average yearly utility rates, with 0.86 QALY for Botox and 0.83 QALY for InterStim. Botox had higher average QALY values than InterStim at all time points, but no differences were greater than the minimally important difference. Until appropriately powered randomized controlled trials are available, our model would advocate the use of either strategy for urge urinary incontinence, which is refractory to antimuscarinic therapy.
